Epigenetics of nicotine: Another nail in the coughing

Science Translational Medicine

Volumn 3, Issue 107, 2011, Pages

  Volkow, Nora D ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; NICOTINE; THEOPHYLLINE; TRANSCRIPTION FACTOR FOSB; VORINOSTAT;

CANNABIS ADDICTION; CIGARETTE SMOKING; EPIGENETICS; FOSB GENE; GENE; GENE EXPRESSION; HISTONE ACETYLATION; HUMAN; LONG TERM EXPOSURE; LONG TERM POTENTIATION; MATERNAL SMOKING; NICOTINE REPLACEMENT THERAPY; NONHUMAN; NUCLEUS ACCUMBENS; PLACE PREFERENCE; PRIORITY JOURNAL; REINFORCEMENT; REVIEW; REWARD; TERATOGENICITY; TOBACCO DEPENDENCE; TRANSCRIPTION INITIATION; ANIMAL; ARTICLE; COCAINE DEPENDENCE; DRUG EFFECT; GENETIC EPIGENESIS; GENETICS; METABOLISM; MOUSE;

ANIMALS; COCAINE; COCAINE-RELATED DISORDERS; EPIGENESIS, GENETIC; HISTONE DEACETYLASES; MICE; NICOTINE;

EID: 80455143367     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003278     Document Type: Review

References (24)

1. A. Levine, Y. Huang, B. Drisaldi, E. A. Griffin Jr., D. D. Pollak, S. Xu, D. Yin, C. Schaffran, D. B. Kandel, E. R. Kandel, Molecular mechanism for a gateway drug: Epigenetic changes initiated by nicotine prime gene expression by cocaine. Sci. Transl. Med. 3, 107ra109 (2011).
2. D. B. Kandel, Ed., Stages and Pathways of Drug Involvement: Examining the Gateway Hypothesis (Cambridge Univ. Press, Cambridge, 2002).
3. S. T. Leatherdale, R. Ahmed, Alcohol, marijuana, and tobacco use among Canadian youth: Do we need more multi-substance prevention programming? J. Prim. Prev. 31, 99-108 (2010).
4. L. M. Tullis, R. Dupont, K. Frost-Pineda, M. S. Gold, Marijuana and tobacco: A major connection? J. Addict. Dis. 22, 51-62 (2003).
5. M. Vaughn, J. Wallace, B. Perron, V. Copeland, M. Howard, Does marijuana use serve as a gateway to cigarette use for high-risk African-American youth? Am. J. Drug Alcohol Abuse 34, 782-791 (2008).
6. D. B. Kandel, Does marijuana use cause the use of other drugs? JAMA 289, 482-483 (2003).
7. L. Degenhardt, L. Dierker, W. T. Chiu, M. E. Medina-Mora, Y. Neumark, N. Sampson, J. Alonso, M. Angermeyer, J. C. Anthony, R. Bruffaerts, G. de Girolamo, R. de Graaf, O. Gureje, A. N. Karam, S. Kostyuchenko, S. Lee, J. P. Lépine, D. Levinson, Y. Nakamura, J. Posada-Villa, D. Stein, J. E. Wells, R. C. Kessler, Evaluating the drug use "gateway"theory using cross-national data: Consistency and associations of the order of initiation of drug use among participants in the WHO World Mental Health Surveys. Drug Alcohol Depend. 108, 84-97 (2010).
8. W. D. Hall, M. Lynskey, Is cannabis a gateway drug? Testing hypotheses about the relationship between cannabis use and the use of other illicit drugs. Drug Alcohol Rev. 24, 39-48 (2005).
9. S. E. Hyman, R. C. Malenka, Addiction and the brain: The neurobiology of compulsion and its persistence. Nat. Rev. Neurosci. 2, 695-703 (2001).
10. P. W. Kalivas, R. T. Lalumiere, L. Knackstedt, H. Shen, Glutamate transmission in addiction. Neuropharmacology 56 (suppl. 1), 169-173 (2009).
11. P. W. Kalivas, N. D. Volkow, New medications for drug addiction hiding in glutamatergic neuroplasticity. Mol. Psychiatry 16, 974-986 (2011).
12. C. A. McClung, P. G. Ulery, L. I. Perrotti, V. Zachariou, O. Berton, E. J. Nestler, DeltaFosB: A molecular switch for long-term adaptation in the brain. Brain Res. Mol. Brain Res. 132, 146-154 (2004).
13. N. Hiroi, J. R. Brown, C. N. Haile, H. Ye, M. E. Greenberg, E. J. Nestler, FosB mutant mice: Loss of chronic cocaine induction of Fos-related proteins and heightened sensitivity to cocaine's psychomotor and rewarding eff ects. Proc. Natl. Acad. Sci. U.S.A. 94, 10397-10402 (1997).
14. W. Renthal, A. Kumar, G. Xiao, M. Wilkinson, H. E. Covington 3rd, I. Maze, D. Sikder, A. J. Robison, Q. LaPlant, D. M. Dietz, S. J. Russo, V. Vialou, S. Chakravarty, T. J. Kodadek, A. Stack, M. Kabbaj, E. J. Nestler, Genome-wide analysis of chromatin regulation by cocaine reveals a role for sirtuins. Neuron 62, 335-348 (2009).
15. E. J. Nestler, Review. Transcriptional mechanisms of addiction: Role of DeltaFosB. Philos. Trans. R. Soc. Lond. B Biol. Sci. 363, 3245-3255 (2008).
16. J. D. Hawk, C. Florian, T. Abel, Post-training intrahippocampal inhibition of class I histone deacetylases enhances long-term object-location memory. Learn. Mem. 18, 367-370 (2011).
17. A. G. Kazantsev, L. M. Thompson, Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat. Rev. Drug Discov. 7, 854-868 (2008).
18. Q. LaPlant, E. J. Nestler, CRACKing the histone code: Cocaine's eff ects on chromatin structure and function. Horm. Behav. 59, 321-330 (2011).
19. E. Menegola, F. Di Renzo, M. L. Broccia, M. Prudenziati, S. Minucci, V. Massa, E. Giavini, Inhibition of histone deacetylase activity on specific embryonic tissues as a new mechanism for teratogenicity. Birth Defects Res. B Dev. Reprod. Toxicol. 74, 392-398 (2005).
20. A. Hackshaw, C. Rodeck, S. Boniface, Maternal smoking in pregnancy and birth defects: A systematic review based on 173 687 malformed cases and 11.7 million controls. Hum. Reprod. Update 17, 589-604 (2011).
21. J. E. Bruin, H. C. Gerstein, A. C. Holloway, Long-term consequences of fetal and neonatal nicotine exposure: A critical review. Toxicol. Sci. 116, 364-374 (2010).
22. P. Szulakowski, A. J. Crowther, L. A. Jiménez, K. Donaldson, R. Mayer, T. B. Leonard, W. MacNee, E. M. Drost, The eff ect of smoking on the transcriptional regulation of lung inflammation in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 174, 41-50 (2006).
23. J. A. Marwick, P. A. Kirkham, C. S. Stevenson, H. Danahay, J. Giddings, K. Butler, K. Donaldson, W. Macnee, I. Rahman, Cigarette smoke alters chromatin remodeling and induces proinflammatory genes in rat lungs. Am. J. Respir. Cell Mol. Biol. 31, 633-642 (2004).
24. Acknowledgments: The author thanks R. Baler for editorial assistance and help with figures. Competing interests: The author is the director of the U.S. National Institute on Drug Abuse, which administered a grant awarded to carry out some of the work discussed herein.